Is Mounjaro Better Than Wegovy? What the Evidence Actually Says

Mounjaro and Wegovy are both once-weekly injectable medicines, but they work through different pathways — and that distinction is worth understanding factually.

Active substances and mechanisms

• Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist. It activates two appetite-regulating pathways simultaneously — both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor.
• Wegovy contains semaglutide, a GLP-1 receptor agonist only. It acts on a single pathway — the same GLP-1 system that also underlies Ozempic (a different-dose semaglutide formulation used primarily in type 2 diabetes management).

What they have in common

Both medicines are commonly reported to reduce appetite and increase feelings of fullness, partly through slowing gastric emptying — an effect many people notice more strongly in the early weeks. Both are prescription-only and are typically started at a low dose, with any adjustment made by the prescriber over time. Neither is insulin, and neither replaces the need for dietary awareness and clinical supervision.

How do they compare to other options?

Questions like "is Wegovy better than Ozempic" or "is Mounjaro better than Ozempic for weight loss" often arise because semaglutide appears in both products at different doses and licensed indications — you can read more about the relationship between Wegovy and Ozempic for a clearer picture. Older medicines such as orlistat and liraglutide (Saxenda) work through different mechanisms entirely, and comparisons between them and newer GLP-1 medicines are best discussed with a prescriber who knows your full history.

Does the evidence say one works better?

Clinical trials have examined each medicine separately, and some head-to-head data exists in the research literature. However, interpreting that data in the context of your own situation — your health history, other medicines, and personal goals — is a clinical judgement, not something a comparison article can make for you. Some people report that one worked better for them individually; that variation is real and is part of why prescriber guidance matters. For a deeper look at how tirzepatide works, see how Mounjaro works as a dual GIP and GLP-1 agonist. If cost is also a consideration in your thinking, the page on why Mounjaro's pricing is what it is addresses that context without quoting figures.

GLP Trackr is built for people already on Mounjaro or Wegovy, and it supports both medicines equally. Whatever you have been prescribed, the most useful thing you can do day-to-day is track consistently — and that is exactly where the app helps.

The insights and analytics feature is particularly relevant here: because Mounjaro and Wegovy can affect appetite, energy, and side effects differently from person to person, tracking your own patterns over time gives you real, personal data — not just population averages. The app surfaces correlations between your logged data points (sleep, food, weight, how you feel) so you can see what is actually happening in your own journey, rather than relying on generalisations.

Alongside that, the side-effect tracker lets you log how you feel after each dose — useful whether you are navigating nausea in the early weeks or noticing changes as your dose is adjusted by your prescriber. You can also read about what effectiveness on Wegovy looks like in practice if that is the medicine you have been given.

Any decision about which medicine is right for you, or whether to switch, is one to make with your prescriber — they have the full clinical picture. GLP Trackr helps you arrive at those conversations with clear, organised data about your own experience rather than vague recollections.

Both medicines are available on iOS and Android. Start tracking your journey with a free 7-day trial — download GLP Trackr on the App Store or Google Play and see what your own data reveals.